Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | TKT | P29401 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2953593 | 0.98 | KMT2A (0.54) | KMT2AALDH1A1MEN1KDM4EAPOBEC3G | |
| SCHEMBL6936407 | 0.79 | TKT (0.46) | TKT | |
| Hydrochloric Acid SCHEMBL3846668 | 0.78 | KMT2A (0.54) | KMT2AMEN1KDM4ETP53MAPT | |
| Hydrochloric Acid SCHEMBL3848932 | 0.78 | KMT2A (0.54) | KMT2AKDM4ELMNA | |
| Bromide SCHEMBL2946803 | 0.78 | TKT (0.46) | TKTOPRM1OPRD1 | |
| SCHEMBL6939902 | 0.75 | TKT (0.54) | KMT2AALDH1A1MEN1KDM4ETKT | |
| Bromide SCHEMBL2952819 | 0.74 | TKT (0.53) | KMT2AALDH1A1MEN1KDM4ETKT | |
| Bromide SCHEMBL3847295 | 0.72 | KMT2A (0.52) | KMT2AKDM4EOPRM1OPRD1 | |
| SCHEMBL4189301 | 0.71 | ALDH1A1 (0.41) | KMT2AALDH1A1MEN1KDM4EAPOBEC3G | |
| SCHEMBL5014356 | 0.71 | LMNA (0.49) | KMT2AALDH1A1MEN1MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0808163-B1 | USE OF THIAZOLIUM COMPOUNDS FOR PREVENTING AND REVERSING THE FORMATION OF ADVANCED GLYCOSYLATION ENDPRODUCTS | ALTEON INC (US) | 2003-07-23 | — | — | EP | claimed |
| US-6440749-B1 | ADMINISTERING A THIAZOLE COMPOUND | ALTEON. INC. | 2002-08-27 | — | — | US | claimed |
| WO-2009042213-A1 | METHODS OF TREATING OR PREVENTING CARDIAC DISEASE ASSOCIATED WITH A HIGH FAT DIET | SYNVISTA THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| US-20090088461-A1 | Methods of Treating or Preventing Cardiac Disease Associated With a High Fat Diet | SYNVISTA THERAPEUTICS, INC. (US) | 2009-04-02 | — | — | US | disclosed |
| WO-2009023207-A1 | THIAZOLIUM COMPOUNDS FOR TREATING GASTROINTESTINAL COMPLICATIONS | SYNVISTA THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20080132553-A1 | Preventing and reversing the formation of advance glycosylation endproducts | CERAMI ANTHONY | 2008-06-05 | — | — | US | disclosed |
| US-20070025926-A1 | Preventing and reversing the formation of advance glycosylation endproducts | SYNVISTA THERAPEUTICS, INC. | 2007-02-01 | — | — | US | disclosed |
| US-7022719-B2 | Preventing and reversing the formation of advance glycosylation endproducts | ALTEON, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-6440749-B1 | ADMINISTERING A THIAZOLE COMPOUND | ALTEON. INC. | 2002-08-27 | — | — | US | disclosed |
| US-6007865-A | FOR INHIBITING AND REVERSING NONENZYMATIC CROSS-LINKING (PROTEIN AGING), TREATING KIDNEY DAMAGE AND TREATING COMPLICATIONS OF DIABETES, PREVENTING FOOD SPOILAGE | ALTEON INC. | 1999-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088461-A1 | Methods of Treating or Preventing Cardiac Disease Associated With a High Fat Diet | FABP3, TXNRD2, PPARD | KMT2A 3186/4885ALDH1A1 653/4885MEN1 4851/4885 |
| US-20080132553-A1 | Preventing and reversing the formation of advance glycosylation endproducts | AGER, PTMS, OGA | KMT2A 3856/4885ALDH1A1 1576/4885MEN1 3995/4885 |
| US-20070025926-A1 | Preventing and reversing the formation of advance glycosylation endproducts | AGER, PTMS, OGA | KMT2A 3689/4885ALDH1A1 1227/4885MEN1 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.